CSIRO helped to develop a pharmacy guided weight loss program called Impromy and clinically validated a related program called Flexi with the former owner, Probiotec Limited. Probiotec later launched Metabolic C12, another product under the Impromy brand which was not clinically validated by CSIRO.
The way in which CSIRO’s name is currently being used in association with the Impromy program sits outside the scope of what was approved by CSIRO in the original agreement with Probiotec.
CSIRO receives a 1 per cent royalty of all Impromy sales revenue which includes Metabolic C12, and a further 4 per cent for future joint research.
Now that Blackmores has acquired Impromy, we are currently reviewing this legacy contract. As well as addressing the use of CSIRO’s name, we will also be looking to align the future royalties we receive to the Impromy products which we have developed or clinically validated – the Impromy and Flexi weight loss programs.
All revenue we receive from commercial partnerships is reinvested back into science.